Literature DB >> 2464818

Feulgen DNA values in Wilms' tumour in relation to prognosis.

B R Oppedal1, A Glomstein, A Zetterberg.   

Abstract

Single-cell DNA measurements were performed on Feulgen-stained nuclei in 4 mu tumour sections from 30 patients with Wilms' tumour, all treated with initial nephrectomy. Fifteen patients died from their tumours within 2 years of nephrectomy. The remaining 15 had survived for at least 10 years without evidence of recurrence. Based on the histograms, the tumours were classified as being euploid (E type) or aneuploid (A type). Twenty tumours were euploid and 10 aneuploid. The euploid tumours predominated in the group of survivors. The group of 10 aneuploid tumours contained 7 tumour deaths. The tendency for aneuploid tumours to be associated with early tumour death, however, was not statistically significant.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2464818     DOI: 10.1016/S0344-0338(88)80061-X

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  DNA quantitation of Wilms' tumour (nephroblastoma) using flow cytometry and image analysis.

Authors:  S Gururangan; A Dorman; R Ball; B Curran; M Leader; F Breatnach; A O'Meara
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

2.  Separase: a universal trigger for sister chromatid disjunction but not chromosome cycle progression.

Authors:  Karin G Wirth; Gordana Wutz; Nobuaki R Kudo; Chantal Desdouets; Anders Zetterberg; Shahryar Taghybeeglu; Janina Seznec; Germain M Ducos; Romeo Ricci; Nicole Firnberg; Jan-Michael Peters; Kim Nasmyth
Journal:  J Cell Biol       Date:  2006-03-13       Impact factor: 10.539

3.  Developmental context determines latency of MYC-induced tumorigenesis.

Authors:  Shelly Beer; Anders Zetterberg; Rebecca A Ihrie; Ryan A McTaggart; Qiwei Yang; Nicole Bradon; Constadina Arvanitis; Laura D Attardi; Sandy Feng; Boris Ruebner; Robert D Cardiff; Dean W Felsher
Journal:  PLoS Biol       Date:  2004-09-28       Impact factor: 8.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.